Phosphorus binders: Preferences of patients on haemodialysis and its impact on treatment compliance and phosphorus control;Captores del fósforo: Preferencias de los pacientes en hemodiálisis y su repercusión sobre el cumplimiento del tratamiento y el control del fósforo

Nefrologia

Volumn 30, Issue 5, 2010, Pages 522-530

  Arenas, M D ^a   Malek, T ^a   Alvarez Ude F ^b   Gil, M T ^a   Moledous, A ^a   Reig Ferrer, A ^c  

^a HOSPITAL PERPETUO SOCORRO   (Spain)

^b HOSPITAL GENERAL DE SEGOVIA   (Spain)

^c UNIVERSITY OF ALICANTE   (Spain)

Author keywords

Adherence to treatment; Hemodialysis; Phosphate binders; Preferences

Indexed keywords

ACETIC ACID DERIVATIVE; ALUMINUM HYDROXIDE; CALCIUM ACETATE; CALCIUM DERIVATIVE; CHELATING AGENT; LANTHANUM; LANTHANUM CARBONATE; PHOSPHORUS; POLYAMINE; SEVELAMER;

AGED; ARTICLE; ATTITUDE TO HEALTH; BLOOD; CHELATION THERAPY; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DYSPEPSIA; FEMALE; HUMAN; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT PREFERENCE; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; RENAL REPLACEMENT THERAPY; TABLET; TASTE;

ACETATES; AGED; ALUMINUM HYDROXIDE; CALCIUM COMPOUNDS; CHELATING AGENTS; CHELATION THERAPY; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DYSPEPSIA; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LANTHANUM; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT PREFERENCE; PHOSPHORUS; POLYAMINES; QUESTIONNAIRES; RENAL DIALYSIS; TABLETS; TASTE;

EID: 78049243941     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2010.May.10275     Document Type: Article

References (28)

1. Arenas MD, Álvarez-Ude F, Gil MT, et al. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units. Nephrol Dial Transplant 2006; 21:1663-8.
2. Wei M, Taskapan H, Esbaei K, Jassal SV, Bargman JM, Oreopoulos DG. K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them? Int Urol Nephrol 2006;38:739-43.
3. Lorenzo V, Martín-Malo A, Pérez-García R, Torregrosa JV, Vega N, De Francisco AL, et al. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study. Nephrol Dial Transplant 2006;21(2):459-65.
4. Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44(5 Suppl 2):34-8.
5. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67:1179-87.
6. Rodríguez-Benot A, Martín-Malo A, Álvarez-Lara MA, Rodríguez M, Aljama P. Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis 2005;46(1):68-77.
7. Karamanodou C, Clatworthy J, Weinman J, Horne R. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BCM Nephrol 2008;31(9):2.
8. Arenas MD, Malek T, Gil MT, Moledous A, Álvarez-Ude F, Reig-Ferrer A. The challenge of phosphorus control in the hemodialysis patient: a problem of adherence? J Nephrol 2010. In press.
9. Nieuwkerk PT, Sprangers MAG, Burger DM, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med 2001;161:1962-8.
10. Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dosetitration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003;42:96-107.
11. Slatopolsky EA, Burke SK, Dillon MA, and the Renagel study group. Renagel, a nonabsorbed calcium-and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 1999;55:299-307.
12. Sechet A, Hardy P, Hottelart C, Rasombololona M, Abighanem O, Oualim Z, et al. Role of calcium carbonate administration timing in relation to food intake on its efficiency in controlling hyperphosphatemia in patients on maintenance dialysis. Artif Organs 1998;22:564-8.
13. Arenas MD, Malek T, Moledous A, Núñez C, Álvarez-Ude F. Use of aluminum-based phosphate-chelators in hemodialysis in the era of ultrapure water. Nefrologia 2008;28(2):168-173.
14. Sprague SM. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin 2007;23(12):3167-75.
15. Goff SL, Mazor KM, Meterko V, Dodd K, Sabin J. Patients' beliefs and preferences regarding doctors' medication recommendations. J Gen Intern Med 2008;23:236-41.
16. White CA, Jaffey J, Magner P. Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients. Kidney Int 2007;71:312-7.
17. Knobel H, Alonso J, Casado JL, Collazos J, González J, Ruiz I, et al. GEEMA Study Group. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA study. AIDS 2002;16:605-13.
18. Hemmelgarn BR, Manns BJ, Quan H, Ghali WA. Adapting the Charlson Comorbidity Index for use in patients with ESRD. Am J Kidney Dis 2003;42(1):125-32.
19. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23(8):1296-310.
20. Arenas MD, Rebollo P, Malek T, Moledous A, Gil MT, Álvarez-Ude F, et al. A comparative study between two new phosphate binders (Sevelamer and Lanthanum Carbonate) in the routine clinical practice. J Nephrol 2010. In press.
21. Horne R, Buick D, Fisher M, Leake H, Cooper V, Weinman J. Doubts about necessity and concerns about adverse events: identifying the types of beliefs that are associated with non-adherence to HAART. Int J STD AIDS 2004;15:38-44.
22. Lyons AC, Chamberlain K. Health Psychology: A Critical Introduction. Cambridge: Cambridge University Press, 2006.
23. Kammerer J, Garry G, Hartigan M, Carter B, Erlich L. Adherence in patients on dialysis: strategies for success. Nephrol Nurs J 2007;34(5):479-86.
24. Ambrosioni E. Pharmacoeconomic challenges in disease management of hypertension. J Hypertens 2001;(Suppl):S33-S40.
25. Lyons AC, Chamberlain, K. Health Psychology: A Critical Introduction. Cambridge: Cambridge University Press, 2006
26. Kammerer J, Garry G, Hartigan M, Carter B, Erlich L. Adherence in patients on dialysis: strategies for success. Nephrol Nurs J 2007;34(5):479-86.
27. Epstein RM, Peters E. Beyond information: exploring patients' preferences. JAMA 2009;302(2):195-7.
28. Street RL, Makoul G, Arora NK, Epstein RM. How does communication heal? Pathways linking clinician-patient communication to health outcomes. Patient Educ Couns 2009;74(3):295-301.